Format

Send to

Choose Destination
See comment in PubMed Commons below
Hepatobiliary Surg Nutr. 2017 Feb;6(1):7-21. doi: 10.21037/hbsn.2016.11.02.

Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.

Author information

1
Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, USA; ; Department of Diagnostic and Interventional Radiology, Universitätsmedizin Charité, Berlin, Germany.
2
Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, USA.

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare disease and carries a poor prognosis with surgery remaining the only curative treatment option. However, due to the late presentation of symptoms and close proximity of the tumors to central hepatic structures, only about 30% of patients are classified eligible to resection. As for palliative approaches, ICC constitutes a possible indication for loco-regional therapies (LRT). As such, intra-arterial therapies (IAT) are reported to be feasible, safe and effective in inducing tumor response in unresectable ICC. The paradigm of IAT is premised on the selective delivery of embolic, chemotherapeutic agents to the tumor via its feeding arteries, thus allowing dose escalation within the carcinoma and reduction of systemic toxicity. Conventional transcatheter arterial chemoembolization (cTACE) so far remains the most commonly used IAT modality. However, drug-eluting beads (DEB)-TACE was initiated with the idea of more selective targeting of the tumor owing to the combined embolizing as well as drug-eluting properties of the microspheres used in this setting. Moreover, radioembolization is performed by intra-arterial administration of very small spheres containing β-emitting yttrium-90 (Y90-RE) to the site of the tumor. Clinical evidence exists in support of survival benefits for IAT in the palliative treatment of ICC compared to surgery and systemic chemotherapy. As for combination regimens, cTACE, DEB-TACE and Y90-RE are reported to achieve conversion of patients to surgery in a sequential treatment planning and simultaneous IAT combinations may provide a therapeutic option for treatment escalation. Regarding the current status of literature, controlled randomized prospective trials to compare different IAT techniques and combination therapies as well as treatment recommendations for different IAT modalities are needed.

KEYWORDS:

Transarterial chemoembolization; drug-eluting beads (DEB); intra-arterial therapies (IAT); radioembolization

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for AME Publishing Company Icon for PubMed Central
    Loading ...
    Support Center